The article examines the objective, findings, and clinical context described in 4 societies align on 2026–2027 respiratory vaccine guidance.
Approach:
Endorsing societies: The American Thoracic Society, American Academy of Allergy, Asthma & Immunology, American College of Chest Physicians, and Society of Critical Care Medicine unanimously endorsed the guidance on November 5.
Evidence review: A Vaccine Guidance Review Panel evaluated evidence from March through September 2026, including recommendations established before June 2025, independent systematic reviews, and professional society methodologies.
Key Findings:
Updated COVID-19 vaccination is recommended for adults aged 19 years or older. Adults aged 65 years or older should receive two doses per season, 6 months apart; guidance also supports routine vaccination during pregnancy and updated vaccination for health car…
RSV vaccination is recommended for adults aged 75 years or older and adults aged 50 to 74 years at increased risk of severe disease. Maternal RSVpreF vaccination is recommended at 32 weeks 0 days through 36 weeks 6 days of gestation during the seasonal window.
Infants younger than 8 months without adequate protection through maternal vaccination should receive nirsevimab or clesrovimab during their first RSV season.
Annual influenza vaccination is recommended from age 6 months. For adults aged 65 years or older, recombinant, adjuvanted, or high-dose vaccines are preferred when available.
Indicated influenza, RSV, and COVID-19 vaccines may be administered at the same visit without a minimum interval.
Interpretation:
The endorsed guidance covers influenza, RSV, and COVID-19 vaccination across pediatric and adult populations, including people with chronic conditions, pregnant individuals, and immunocompromised people.
Limitations:
The provided article context does not include the full guidance document or detailed evidence ratings.
